Medical use Marijuana

[sunnye]

A synthetic form of one chemical in marijuana, Δ(delta)-9 tetrahydrocannabinol (THC), is a controversial treatment for medical use. The American Marijuana Policy Project, a pro-cannabis organization, claims that cannabis is an ideal therapeutic drug for cancer and AIDS patients, who often suffer from clinical depression, and from nausea and resulting weight loss due to chemotherapy and other aggressive treatments. Other medical uses may included fighting cancer, according to an isolated study by scientists in Italy. This study states that cannabidiol (CBD), a chemical found in marijuana, inhibits growth of cancer cells in animals.

The FDA and comparable authorities in Western Europe, including the Netherlands, have not approved smoked marijuana for any condition or disease. The current view of the United States Food and Drug Administration is that if there is any future of marijuana as a medicine, it lies in its isolated components, the cannabinoids and their synthetic derivatives.

A synthetic version of the cannabinoid THC named dronabinol has been shown to relieve symptoms of anorexia and reduce agitation in elderly Alzheimer's patients. Dronabinol has been approved for use with anorexia in patients with HIV/AIDS and chemotherapy-related nausea. This drug, while demonstrating the effectiveness of cannabis at combating several disorders, is more expensive and less available than "pot" and has not been shown to be effective or safe.

Glaucoma, a condition of increased pressure within the eyeball causing gradual loss of sight, can be treated with medical marijuana to decrease this intraocular pressure. There has been debate for 25 years on the subject. Some data exist, showing a reduction of IOP in glaucoma patients who smoke marijuana, but the effects are short-lived, and the frequency of doses needed to sustain a decreased IOP can cause systemic toxicity. There is also some concern over its use since it can also decrease blood flow to the optic nerve. Marijuana lowers IOP by acting on a cannabinoid receptor on the ciliary body called the CB receptor.Although marijuana is not a good therapeutic choice for glaucoma patients, it may lead researchers to more effective, safer treatments. A promising study shows that agents targeted to ocular CB receptors can reduce IOP in glaucoma patients who have failed other therapies.

Medical marijuana is used for analgesia, or pain relief. “Marijuana is used for analgesia only in the context of a handful of illnesses (e.g., headache, dysentery, menstrual cramps, and depression) that are often cited by marijuana advocates as medical reasons to justify the drug being available as a prescription medication.” It is also reported to be beneficial for treating certain neurological illnesses such as epilepsy, and bipolar disorder. Case reports have found that cannabis can relieve tics in people with obsessive compulsive disorder and Tourette syndrome. Patients treated with tetrahydrocannabinol, the main psychoactive chemical found in cannabis, reported a significant decrease in both motor and vocal tics, some of 50% or more.Some decrease in obsessive-compulsive behavior was also found.A recent study has also concluded that cannabinoids found in cannabis might have the ability to prevent Alzheimer's disease. THC has been shown to reduce arterial blockages.

Another use for medical marijuana is movement disorders. Marijuana is frequently reported to reduce the muscle spasms associated with multiple sclerosis; this has been acknowledged by the Institute of Medicine, but it noted that these abundant anecdotal reports are not well-supported by clinical data. Evidence from animal studies suggests that there is a possible role for cannabinoids in the treatment of certain types of epileptic seizures. Marijuana "numbs" the nervous system slightly, possibly preventing shock. A synthetic version of the major active compound in cannabis, THC, is available in capsule form as the prescription drug dronabinol (Marinol) in many countries. The prescription drug Sativex, an extract of cannabis administered as a sublingual spray, has been approved in Canada for the treatment of multiple sclerosis.